Moreover, Wilkinson et al. found that high RUNX1 expression is associated with a detectable level of MRD on the 29th day of therapy in ALL patients with MLL fusion genes, and thus with a poorer clinical course and risk of early relapse [34]. Here, KMT2A is linked to acute lymphoblastic leukemia.